FORMULATION DESIGN OF EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS: OPTIMIZATION OF FORMULATION USING STATISTICAL EXPERIMENTAL DESIGN

被引:2
作者
Chinta, Rajarao [1 ]
Pilli, Rohini [1 ]
机构
[1] Acharya Nagarjuna Univ, Univ Coll Pharmaceut Sci, Dept Pharmaceut, Guntur 522510, Andhra Pradesh, India
来源
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH | 2020年 / 11卷 / 12期
关键词
Empagliflozin; Metformin hydrochloride; Extended Release; Factorial design; Kinetic models; FIXED-DOSE COMBINATION;
D O I
10.13040/IJPSR.0975-8232.11(12).6434-47
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of the present study was to develop Empagliflozin and Metformin hydrochloride extended release tablets, comprising immediate release empagliflozin and extended release metformin hydrochloride in a single tablet. Wet granulation process was employed to develop extended release part metformin hydrochloride. Impact of various formulation variables in extended release part was assessed using statistical interpretation such as analysis of variance. A 3(2) (two factor, three level) factorial design was employed to study the effect of independent variables (binder concentration [sodium CMC] and ER polymer [HPMC K100M CR/polyethylene oxide/carbopol] concentration)on dependent variables (drug release at 1, 4 and 10h). Optimization was done by fitting experimental data to the software program (design expert). The design space for formulation variables and its influence on drug release was developed. In-vitro release data observed from the optimized formulation was fitted into various kinetic equations. Extended release part drug release was extended for 12 h following zero order kinetics and non-fickian diffusion process. Extended drug delivery system of empagliflozin and metformin hydrochloride extended release tablets was successfully developed by employing granulation technology and formulation optimization facilitated by experimental design.
引用
收藏
页码:6434 / 6447
页数:14
相关论文
共 10 条
[1]  
[Anonymous], 2009, International Conference on Harmonization Guidance for Industry-Q8 (R2) Pharmaceutical Development
[2]  
Dash S, 2010, ACTA POL PHARM, V67, P217
[3]   Combination of Empagliflozin and Metformin Therapy: A Consideration of its Place in Type 2 Diabetes Therapy [J].
Goldman, Jennifer D. .
CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2018, 11
[4]   Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes [J].
Hu, Jingbo ;
Zou, Ping ;
Zhang, Shuo ;
Zhou, Minzhi ;
Tan, Xueying .
EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (18) :2471-2477
[5]   Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review [J].
Kedia, Rohit ;
Kulkarni, Supriya ;
Ross, Meredith ;
Shivaswamy, Vijay .
PATIENT PREFERENCE AND ADHERENCE, 2016, 10 :1999-2006
[6]  
Khan H, 2017, RES J PHARM TECH, V10, P1085
[7]  
Kumari MS, 2018, RES J PHARM TECH, V11, P4119
[8]  
Moore J.W., 1996, PHARM TECHNOLOGIES, V20, P64
[9]   Design of experiments (DoE) in pharmaceutical development [J].
Politis, Stavros N. ;
Colombo, Paolo ;
Colombo, Gaia ;
Rekkas, Dimitrios M. .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2017, 43 (06) :889-901
[10]  
United States Pharmacopeial Convention Inc, 2019, S PHARMACOPOEIA NATL, P2824